Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Emerging Therapies for Duchenne Muscular Dystrophy

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

March 9, 2026

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

On March 8, 2026, Dyne Therapeutics, Inc. (Nasdaq: DYN) announced additional positive data from the ongoing Phase 1/2 DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in...

February 26, 2026

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

On February 26, 2026, Entrada Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent business updates. This full release can...

February 20, 2026

Roche Shares Update on the Investigation of Satralizumab for Bone Health and the SHIELD DMD Study

On February 20, 2026, Roche shared an important update in a community letter regarding their work in bone health in Duchenne and the SHIELD DMD study. Read more by visiting...

February 17, 2026

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

On February 17, 2026, Entrada Therapeutics, Inc. announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight patients...

February 13, 2026

PTC Therapeutics Provides Regulatory Update on Translarna™

On February 12, 2026, PTC Therapeutics, Inc. announced that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy...

February 12, 2026

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

On February 12, 2026, Satellos Bioscience Inc, announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for...

Programs

Events